Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 4/20 | 0.36 |
| ▸ | PTK2B | Q14289 | 2/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | NOS3 | P29474 | 2/20 | 0.36 |
| ▸ | NOS1 | P29475 | 2/20 | 0.36 |
| ▸ | NOS2 | P35228 | 2/20 | 0.36 |
| ▸ | PKM | P14618 | 1/20 | 0.32 |
| ▸ | DRD4 | P21917 | 3/20 | 0.32 |
| ▸ | PIKFYVE | Q9Y2I7 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 3/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | ATM | Q13315 | 1/20 | 0.31 |
| ▸ | DRD2 | P14416 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | ACHE | P22303 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | BPTF | Q12830 | 1/20 | 0.31 |
| ▸ | LNPEP | Q9UIQ6 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21127855 | 0.80 | DRD4 (0.31) | GAAPTK2BSMN1; SMN2DRD4HPGD | |
| SCHEMBL24975328 | 0.80 | DRD4 (0.37) | GAAPTK2BSMN1; SMN2DRD4HPGD | |
| SCHEMBL25681268 | 0.79 | DRD4 (0.31) | GAAPTK2BSMN1; SMN2DRD4HPGD | |
| SCHEMBL17344774 | 0.76 | NOS3 (0.33) | GAAPTK2BNOS3NOS1NOS2 | |
| SCHEMBL21625487 | 0.75 | HTT (0.45) | GAASMN1; SMN2HPGDKDM4EALDH1A1 | |
| SCHEMBL30112208 | 0.75 | HTT (0.45) | GAASMN1; SMN2HPGDKDM4EALDH1A1 | |
| SCHEMBL21637172 | 0.75 | — | — | |
| SCHEMBL21625485 | 0.73 | NLRP3 (0.35) | SMN1; SMN2PKMHPGDKDM4EALDH1A1 | |
| SCHEMBL30043363 | 0.73 | NLRP3 (0.35) | SMN1; SMN2PKMHPGDKDM4EALDH1A1 | |
| SCHEMBL28538564 | 0.72 | LNPEP (0.33) | GAASMN1; SMN2HPGDKDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12617802-B2 | Sulfonimidamide compounds as NLRP3 modulators | GENENTECH, INC. (US) | 2026-05-05 | — | — | US | disclosed |
| US-20230159555-A1 | SULFONIMIDAMIDE COMPOUNDS AS NLRP3 MODULATORS | GENENTECH, INC. (US) | 2023-05-25 | — | — | US | disclosed |
| US-20230159555-A1 | SULFONIMIDAMIDE COMPOUNDS AS NLRP3 MODULATORS | GENENTECH, INC. (US) | 2023-05-25 | — | — | US | disclosed |
| US-20230159555-A1 | SULFONIMIDAMIDE COMPOUNDS AS NLRP3 MODULATORS | GENENTECH, INC. (US) | 2023-05-25 | — | — | US | disclosed |
| US-11560391-B2 | Sulfonylurea compounds as inhibitors of interleukin-1 activity | GENENTECH, INC. (US) | 2023-01-24 | — | — | US | disclosed |
| US-11560391-B2 | Sulfonylurea compounds as inhibitors of interleukin-1 activity | GENENTECH, INC. (US) | 2023-01-24 | — | — | US | disclosed |
| CN-115461120-A | Sulfonylimide compounds as NLRP3 modulators | 豪夫迈·罗氏有限公司 | 2022-12-09 | — | — | CN | disclosed |
| EP-3823726-A1 | SULFONYLUREA COMPOUNDS AS INHIBITORS OF INTERLEUKIN-1 ACTIVITY | F. Hoffmann-La Roche SA (CH) | 2021-05-26 | — | — | EP | disclosed |
| CN-112437683-A | Sulfonylurea compounds useful as inhibitors of interleukin-1 activity | 豪夫迈·罗氏有限公司 | 2021-03-02 | — | — | CN | disclosed |
| WO-2020018970-A1 | SULFONYLUREA COMPOUNDS AS INHIBITORS OF INTERLEUKIN-1 ACTIVITY | GENENTECH, INC. (US) | 2020-01-23 | — | — | WO | disclosed |
| WO-2020018970-A1 | SULFONYLUREA COMPOUNDS AS INHIBITORS OF INTERLEUKIN-1 ACTIVITY | GENENTECH, INC. (US) | 2020-01-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230159555-A1 | SULFONIMIDAMIDE COMPOUNDS AS NLRP3 MODULATORS | NLRP3, NLRP1, PYCARD | GAA 2193/4885PTK2B 3226/4885SMN1; SMN2 1849/4885 |
| US-12617802-B2 | Sulfonimidamide compounds as NLRP3 modulators | NLRP3, NLRP1, PYCARD | GAA 4667/4885PTK2B 1424/4885SMN1; SMN2 2586/4885 |
| US-11560391-B2 | Sulfonylurea compounds as inhibitors of interleukin-1 activity | IL1B, IL1A, IL18 | GAA 497/4885PTK2B 3956/4885SMN1; SMN2 2409/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.